Potential game changer for treatment and containment
A new test can accurately diagnose Ebola virus disease within minutes, providing clinicians with crucial information for treating patients and containing outbreaks.
Researchers from Harvard Medical School, Partners In Health and Boston Children’s Hospital have shown that a new commercially developed rapid diagnostic test performed at bedside was as sensitive as the conventional laboratory-based method used for clinical testing during the recent outbreak in Sierra Leone. The results are published in The Lancet.
While the West African Ebola epidemic has slowed since its peak last fall, the crisis simmers on; there were still 24 confirmed cases of Ebola reported in Guinea and Sierra Leone in the week ending June 14.
To fight Ebola, the first step is to determine which patients are sick with the disease and which with other illnesses with a similar presentation. To use the currently recommended molecular approach, laboratories must be built and samples of highly infectious blood must be drawn, often with unsafe needles and syringes, and then shipped over potentially great distances at substantial risk to the health care workers involved in the process. Then, clinicians and patients must wait for results–sometimes for several days.
These obstacles and delays prevent timely diagnosis and treatment, and also result in individuals without Ebola being admitted to holding units where they may become infected with the virus, the researchers said.
“Simplifying the process and speeding up diagnosis could have a major impact,” said Nira Pollock, senior author of the paper and HMS assistant professor of medicine and associate medical director of the Infectious Diseases Diagnostic Laboratory at Boston Children’s Hospital.
As the Ebola outbreak in West Africa began to surge in 2014, Pollock and Partners In Health researcher Jana Broadhurst worked with the research core of the HMS Department of Global Health and Social Medicine to reach out to teams around the world who were developing diagnostic tools that would enable clinicians to diagnose Ebola patients quickly.
One candidate, the ReEBOV Antigen Rapid Test, developed by Corgenix, seemed like a promising tool. Working with colleagues at Partners In Health and the Ministry of Health and Sanitation in Sierra Leone, the HMS team was able to plug into an environment that allowed it to train local technicians to perform the test and help collect data for the study. The team at the Public Health England lab at Port Loko, where clinical samples were routinely sent for standard molecular diagnostic testing, were also key collaborators. Corgenix donated test kits to the HMS team.
The field trial took place at two treatment centers operated by the Ministry of Health and Sanitation of Sierra Leone and supported by PIH, where 106 patients suspected of having Ebola were tested during February 2015 using the rapid diagnostic test (performed on a fingerstick blood sample at the point of care). The patients were also tested using the standard RT-PCR (performed on plasma in the laboratory). Both rapid diagnostic tests, on whole blood, and RT-PCR, on plasma, were also performed on 284 samples in the laboratory.
The rapid diagnostic test detected all confirmed cases of Ebola that were positive by the benchmark test in both point-of-care and laboratory testing with sensitivity of 100 percent (identifying all patients with Ebola found by the benchmark method), and a specificity of 92 percent (few false positives).
Surprisingly, the study also showed that the standard RT-PCR test, under the conditions deployed in the field, was itself an imperfect reference standard.
Both tests failed to detect a small number of Ebola cases that had been detected by an alternative lab test that was more sensitive than the benchmark test but was not available for wide usage. All of the missed cases showed very low levels of virus. The authors caution that given the limitations of the performance of the benchmark RT-PCR reference test in patients with low levels of the virus, more research is needed to assess how the new rapid diagnostic test will perform in patients still in the early stages of Ebola virus disease.
The Latest on: Rapid Ebola diagnostic
via Google News
The Latest on: Rapid Ebola diagnostic
- Speedy, portable Ebola test fits in a backpackon December 16, 2019 at 4:00 pm
“We set out to create a rapid, point-of-care diagnostic that could look for malaria, Ebola, and other pathogens that are often found in these regions,” says Connor, a virologist at Boston University’s ...
- Ebola Preparedness and Response Updates from FDAon November 15, 2019 at 5:00 am
Currently, there are 10 Ebola diagnostic tests available for emergency use under FDA’s Emergency Use Authorization (EUA) authority (1 rapid antigen test and 9 molecular tests). January 2017: Guidance ...
- The doctor who developed the Ebola test kiton November 9, 2019 at 1:35 pm
PPU photo In 2014, when the Ebola epidemic broke out in West Africa, Dr Misaki Wayengera was one of the top Ugandan physicians who were dispatched to contain the virus. At the time, he was also ...
- FDA Authorizes Emergency Use of First Ebola Fingerstick Test With Portable Readeron November 2, 2019 at 5:00 pm
This is the second Ebola rapid antigen fingerstick test available under EUA, but the first that uses a portable battery-operated reader, which can help provide clear diagnostic results outside of ...
- WHO Says Rapid, Sensitive, Safe and Simple Ebola Diagnostic Tests are Needed Urgentlyon November 2, 2019 at 5:00 pm
Perhaps most importantly, a recent research study, based on the management of more than 700 Ebola patients in Monrovia, Liberia, strongly suggests that clinical decisions guided by results from rapid ...
- Ebola Outbreak a Proving Ground for Lucigen’s Rapid Diagnosticon November 2, 2019 at 5:00 pm
“Our goal is have a rapid point-of-care Ebola diagnostic test available in months, not years,” Shenoi said in an e-mail message. “The global crisis is too great, and one of the major unmet needs is ...
- First Rapid Diagnostic Test for Detecting Ebola Virus Allowed by FDAon October 11, 2019 at 10:03 am
Officials from the FDA have allowed marketing of a rapid diagnostic test (RDT) to help detect Ebola virus antigens in the bloodstream from certain living individuals and samples from recently deceased ...
- Healthwatch: FDA Allowing Marketing Of First Rapid Diagnostic Test For Ebolaon October 11, 2019 at 9:48 am
A look at the latest health news headlines. One Person, Firefighter Injured In West Baltimore FireTwo people, including a firefighter, were injured in a two-alarm fire in west Baltimore Thursday night ...
- Healthwatch: FDA Allowing Marketing Of First Rapid Diagnostic Test For Ebolaon October 11, 2019 at 9:45 am
A look at the latest health news headlines. Thief Leaves Behind Thank You Note After Taking PackageAn unbelievable story, a porch pirate leaves a note for the person who's package was stolen. 5 hours ...
- FDA approves OraSure's 30-minute Ebola virus diagnosticon October 11, 2019 at 7:46 am
The FDA approved its first rapid in vitro diagnostic for confirming Ebola virus infections. The single-use OraQuick Ebola test developed by OraSure Technologies searches for virus antigens in samples ...
via Bing News